ProQR Therapeutics (PRQR) Equity Ratio (2021 - 2025)

ProQR Therapeutics (PRQR) has disclosed Equity Ratio for 5 consecutive years, with 0.44 as the latest value for Q4 2025.

  • Quarterly Equity Ratio fell 16.95% to 0.44 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.44 through Dec 2025, down 16.95% year-over-year, with the annual reading at 0.44 for FY2025, 16.95% down from the prior year.
  • Equity Ratio hit 0.44 in Q4 2025 for ProQR Therapeutics, down from 0.53 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.54 in Q4 2021 to a low of 0.3 in Q4 2023.
  • Historically, Equity Ratio has averaged 0.44 across 5 years, with a median of 0.44 in 2025.
  • Biggest five-year swings in Equity Ratio: dropped 28.51% in 2022 and later skyrocketed 75.65% in 2024.
  • Year by year, Equity Ratio stood at 0.54 in 2021, then decreased by 28.51% to 0.39 in 2022, then decreased by 22.88% to 0.3 in 2023, then surged by 75.65% to 0.53 in 2024, then fell by 16.95% to 0.44 in 2025.
  • Business Quant data shows Equity Ratio for PRQR at 0.44 in Q4 2025, 0.53 in Q4 2024, and 0.3 in Q4 2023.